Marc Lakmaaker Vice President, Investor Relations Disclaimer - - PowerPoint PPT Presentation

marc lakmaaker
SMART_READER_LITE
LIVE PREVIEW

Marc Lakmaaker Vice President, Investor Relations Disclaimer - - PowerPoint PPT Presentation

Creating a Preeminent Global Cannabis Company Marc Lakmaaker Vice President, Investor Relations Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in contained in this presentation constitutes forward-looking


slide-1
SLIDE 1

Creating a Preeminent Global Cannabis Company

Marc Lakmaaker

Vice President, Investor Relations

slide-2
SLIDE 2

2

Disclaimer

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this presentation include, but are not limited to, statements with respect to accretive earnings, statements with respect to the funded production capacity which may not be achieved or realized within the time frames stated or at all, the anticipated size and or revenue associated with the adult consumer market in Canada and the global market for medical marijuana. Forward looking statements are based on certain assumptions regarding Aurora, including expected growth, results of operations, performance, industry trends and growth opportunities. While Aurora considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Recipients are cautioned not to place undue reliance on forward-looking statements contained herein. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the early stage of the cannabis industry in Canada generally, realization of funded production estimates, income tax and regulatory matters; the ability of Aurora to implement its business strategies; competition; currency and interest rate fluctuations; the risk of difficulties in the integration of Aurora and MedReleaf, the estimated size of the adult consumer market for cannabis in Canada, the estimated size of the global medical cannabis market and other risks. Recipients are cautioned that the foregoing risks are not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this presentation are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Aurora disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Factors that could cause anticipated opportunities and actual results to differ materially include, but are not limited to, matters referred to above and elsewhere in Aurora’s public filings and the material change reports that will be filed in respect of this Transaction, which are, or will be, available

  • n SEDAR.
slide-3
SLIDE 3

3

A Platform for Accelerated Growth

Industry Leading Scale Extensive Distribution Channels in Canada and Internationally Enhanced Capital Markets Profile Proven Execution & Agility Across Value Chain Innovation and R&D Excellence Low Production Costs and Industry Leading Yields Award Winning Product Lines Support Brand Leadership

$

Enhanced Diversification

slide-4
SLIDE 4

4

11 Production Facilities – 570,000 kg/year Funded Capacity

AURORA AURORA AURORA AURORA AURORA AURORA AURORA AURORA MEDRELEAF MEDRELEAF MEDRELEAF Total TGOD(1) TGOD(1) Facility Alberta (Mountain) Quebec (Vie) Quebec (Lachute) Sask. (Saskatoon) CanniMed Alberta (Sky) Denmark (Odense) Denmark (Nordic) Alberta (Sun) Ontario (Markham) Ontario (Bradford) Ontario (Exeter) Alberta, Ontario, Quebec, Sask., Denmark Ontario (Hamilton) Quebec (Valleyfield) Footprint (sq.ft) 55,000 40,000 48,000 97,000 800,000 100,000 1,000,000 1,200,000 55,000 210,000 1,000,000 4,505,000 150,000 820,000 Status Operating since 2015 Complete and licensed in Nov 2017 Completion in early calendar 2018 Working on GMP certification Expansion started Licensed in January 2018 Completion by mid- 2018 Retrofitting in progress Cultivation to commence in summer 2018 Recently announced facility First planting in H1 2019 Completion in H2 2019 Operating since 2014 Yields 300 g / sq. ft. Expected to be fully

  • perational

by mid- 2018 First harvest in Q1 2019 Adjacent land with space for ~1.5mm sq.

  • ft. facility

Expected completion in Q4 2018 Expected completion in Q2 2019 Funded Capacity (kg / yr) 4,800 4,000+ 4,500+ 19,000 100,000+ 8,000 120,000+ 150,000+ 7,000 28,000 105,000 570,000+ 14,000 102,000 Estimated

Completion Date Nov-14 Apr-17 Nov-17 Mar-18 H2 2018 H2 2018 H2 2019 H2 2019 2014 H2 2018 H1 2019(3) Q4 2018 Q2 2019 1. Aurora has the option to incrementally increase its ownership interest in TGOD to over 50% upon TGOD achieving certain operational milestones. 2. The sum of Aurora and MedReleaf’s announced funded capacity is 430,000+ kg and 140,000+ kg per year, respectively; total funded capacity of Aurora includes proportionate share of TGOD (23,000 kg per annum). 3. Based on first harvest.

(2)

Rapid Conversion of Remaining Funded Capacity Into Production Capacity By End of 2019

Industry Leading Scale

slide-5
SLIDE 5

5

Aurora Sky ky

  • 100,000+ kg per year at full capacity
  • Anticipated production costs <$1 per gram
  • Closed system
  • Highly Automated
  • Complete control over environmental

conditions

  • Customized irrigation and nutrition systems
  • Specialty glass
  • Advanced disease, pest and plant stress

prevention systems

  • Strategically located at Edmonton

International Airport

slide-6
SLIDE 6

6

Cayman Islands

First ever sale of commercial cannabis oils

Denmark(1)

Owns 51% of Aurora Nordic where a 1,000,000 sq ft facility is being built and a 100,000 sq ft retrofit greenhouse

Germany

Pedanios(1), Aurora’s wholly owned wholesale importer / exporter / distributer sells cannabis to pharmacies, allowing for full margin capture. Increased EU reach and distribution capabilities through partnership with Heinrich Klenk Supply agreement with Cannamedical Pharma Introducing CanvasRx model to seed and accelerate growth

Extensive Distribution Channels in Canada and Internationally

South Africa

Definitive agreement to supply cannabis products to Akula Trading 2 Pty Ltd.

Australia

22.9% interest in Cann Group, first Australian company licensed to cultivate medical cannabis First ever shipment of commercial cannabis oils through CanniMed

Australia

JV partner Indica received cannabis cultivation and production license

Italy

Sells cannabis to the Italian government through Pedanios; completed first ever private export from Canada in April-18

Aurora MedReleaf Both Aurora & MedReleaf Brazil

Completed first ICH-GMP certified commercial export and the country’s first import of cannabis-oil

European Union

LOI with Creso Pharma Ltd. to market CMED medical cannabis brands

Canada (Combined)

Operation/construction 9 facilities Established key distributor relationships with SAQ, AGLC, Shoppers, PharmaChoice and Pharmasave, as well as a strategic ownership interest in Alcanna

570,000 kg p.a. funded capacity foundation to feed expanding domestic and international distribution channels

1. Aurora Nordic will focus on the cultivation and sales of cannabis in Denmark, Sweden, Norway, Finland and Iceland through Aurora’s wholly-

  • wned subsidiary, Pedanios.

Malta

slide-7
SLIDE 7

7

Innovation and R&D Excellence

A Science Driven Approach

  • Thousands of data records

collected over 10 years drive enhanced patient experience

  • Clinical research with well-

recognized research centers and leadership, including 11 peer-reviewed publications

  • Developing a Medical

Cannabis Centre of Excellence

  • Strong scientific leadership

team with proven track- record in product development

  • Industry leading combined

science team with ~40 PhDs and MScs

Innovative Product Development

  • Innovative and diverse

product lines, including topical creams and capsules

  • First LP to bring capsules,

topical cream and variety-specific softgel capsules to market

Developing Marketable IP to Deliver Products for Medical and Adult Consumer Use Markets Adding Anandia Labs, the recognized science leader in genetics, breeding and testing

slide-8
SLIDE 8

8

Industry Leading Growth

  • Fastest ramp up,

execution and sales growth achieved relative to other licensed producers

  • High pace of execution

enhances early mover advantage and rapid capitalization on

  • pportunities

Quarterly Revenue Development

(1)

1. Aurora (Pro Forma CanniMed and MedReleaf).

Competitor 2 Competitor 1 $1 $2 $

Quarterly Revenue (C$ mm)

$0.00 $5.00 $10.00 $15.00 $20.00 $25.00 $30.00 $35.00

slide-9
SLIDE 9

9

13-June-18

Strategic Investment in

Choom 5-Jan-18

Strategic Investment in

TGOD 9-Feb-18

Introduces

San Rafael '71 6-Mar-18

Adds the

Woodstock

brand

22-May-18

Strategic Investment in

CTT Pharma

Proven Execution & Agility Across the Value Chain

Acquisitions Branding / Strategic Investments

14-Dec-16

Signs JV MOU with

Radient 8-June-17

Strategic Investment in

HempCo, Food and Fiber 30-Mar-17

Strategic Investment in Australia through investment in

Cann Group 15-Jan-18 22-Feb-18

Strategic Investment in

Alcanna 3-Apr-18

Launched

AltaVie

Brand

2-Oct-17 Acquires B.C. Northern Lights Urban Cultivator 6-Mar-17 Acquires Peloton Pharmaceuticals 26-May-17 Acquires Pedanios a wholesale

importer, exporter, and distributor of medical cannabis in the E.U.

18-Aug-16 Acquires CanvasRx,

a cannabis patient counselling service

5-Dec-17 Acquires Larssen H2 Biopharma 28-Mar-18 Acquires CanniMed Aurora MedReleaf 14-Sep-17

Announces R&D Collaboration and investment in cannabis grow lighting firm

Flora Fotonica Dec-16 Mar-17 Jun-17 Sep-17 Mar-18 Dec-17 12-June-18 Acquires Anandia Laboratories Jun-18 7-June-18

Strategic Investment in

Capcium

Strategic Investment in

Micron Waste 25-July-18 Acquires MedReleaf

slide-10
SLIDE 10

10

Building Cultivation & Extraction Plant Science & Product R&D Consumer Engagement & Brands Distribution

  • Larssen is a design and

engineering consultancy for efficient, high-tech, automated, environmentally controlled greenhouses

  • For over 30 years, has consulted
  • n the design, engineering, and

construction oversight of many

  • f the world's most advanced

greenhouse cultivation facilities.

  • Low-cost, exceptionally high

yield operations

  • Strategic investment in Radient,

disruptive extraction technology

  • Industry leading genetics

research

  • Robust product innovation
  • Medical Centre of Excellence
  • Complementary and ancillary

products, including BC Northern Lights, Hempco

  • Robust domestic &

international distribution networks

  • Established, well-recognized and

respected medical and consumer brands

  • Strong consumer engagement,

with mobile app, customer care and same-day delivery in select provinces

Vertical Integration with Horizontal Diversification

A Global Company with Expertise Across the Value Chain

slide-11
SLIDE 11

11

Checking All the Boxes - A Platform for Accelerated Growth

Industry Leading Scale Extensive Distribution Channels in Canada and Internationally Enhanced Capital Markets Profile Proven Execution & Agility Across Value Chain Innovation and R&D Excellence Low Production Costs and Industry Leading Yields Award Winning Product Lines Support Brand Leadership

$

Enhanced Diversification

slide-12
SLIDE 12

12

Experienced Leadership Team

Terry Booth

CEO

CEO of 6 successful companies 25 years experience in highly regulated industries

Cam Battley

Chief Corporate Officer

Deep experience in pharma and cannabis sectors Board member Cannabis Canada

Steve Dobler

President

Successful entrepreneur, member of many public companies’ board of

  • directors. Responsible for raising

substantial funds for Aurora

Glen Ibbott

CFO

Strong senior financial executive with deep life sciences sector experience

Neil Belot

Chief Global Business Development Officer

Former executive director of Cannabis Canada - Canada's trade association for Licensed Producers

Allan Cleiren

COO

Experienced operational executive with nearly three decades leadership experience at private and public companies

Darryl Vleeming

Chief Information Officer

  • ver 20 years of experience in

Senior IT leadership, project delivery, and IT strategic planning at publicly traded international corporations, with a specific focus on driving business value.

slide-13
SLIDE 13

13

Marc Lakmaaker, Director IR & Corporate Development marc.lakmaaker@auroramj.com Cam Battley Chief Corporate Officer cam@auroramj.com

Contact Information

Investor Relations: 1-855-279-4652